Sonder Capital

Sonder Capital is a Menlo Park venture firm that backs medical device and diagnostics startups at their earliest stages. The firm describes itself as a foundational medtech investor that commits both energy and capital early, with an emphasis on guiding transformative diagnostic and device companies through the long road to commercialization. It is not an AI-focused fund, and its sub-vertical attention is concentrated on medical devices and diagnostics rather than digital health or therapeutics.

Sonder writes checks of roughly $1M to $5M and participates across pre-seed, seed, and Series A rounds. The Menlo Park base suggests a default orientation toward U.S. founders, although geographic restrictions are not specified in available information. Given the early-stage focus and check size, Sonder is most relevant for technical founders building hardware-heavy diagnostic or device companies that need a first or second institutional partner with domain depth.

Founders should approach Sonder with a clear regulatory and commercialization plan, since the firm explicitly frames itself as a guide to commercialization rather than a passive capital provider. Expect diligence focused on clinical validation pathways, IP defensibility, and reimbursement. Pre-seed and seed entrepreneurs without a complete team can still be in scope given the early commitment posture.